Equillium (EQ) Shares Outstanding (Diluted Average) (2021 - 2026)
Equillium (EQ) reported Shares Outstanding (Diluted Average) of $96.3 million for Q1 2026, up 170.55% year-over-year from $35.6 million in Q1 2025, and up 68.01% quarter-over-quarter from $57.3 million in Q4 2025.
Equillium (EQ) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Equillium (EQ) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $96.3 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $96.3 million, up 170.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $96.3 million (up 170.55% YoY), and the FY2025 annual result was $57.3 million, up 62.07% from the prior year.
- Shares Outstanding (Diluted Average) climbed to $96.3 million in Q1 2026 per EQ's latest filing, from $57.3 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $96.3 million in Q1 2026 and troughed at $31.9 million in Q1 2022.
- A 5-year average of $41.3 million and a median of $35.3 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Diluted Average) grew 0.94% in 2025, then soared 170.55% in 2026.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $33.7 million in 2022, then grew by 2.96% to $34.7 million in 2023, then advanced by 1.82% to $35.4 million in 2024, then soared by 62.07% to $57.3 million in 2025, then surged by 68.01% to $96.3 million in 2026.
- Business Quant data shows EQ's Shares Outstanding (Diluted Average) at $96.3 million in Q1 2026, $57.3 million in Q4 2025, and $65.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | 96.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.28 Mn |
| Dec 31, 2025 | 57.30 Mn |
| Sep 30, 2025 | 65.32 Mn |
| Jun 30, 2025 | 35.72 Mn |
| Mar 31, 2025 | 35.59 Mn |
| Dec 31, 2024 | 35.36 Mn |
| Sep 30, 2024 | 35.32 Mn |
| Jun 30, 2024 | 35.27 Mn |
| Mar 31, 2024 | 35.25 Mn |
| Dec 31, 2023 | 34.73 Mn |
| Sep 30, 2023 | 34.58 Mn |
| Jun 30, 2023 | 34.45 Mn |
| Mar 31, 2023 | 34.41 Mn |
| Dec 31, 2022 | 33.73 Mn |
| Sep 30, 2022 | 33.51 Mn |
| Jun 30, 2022 | 33.09 Mn |
| Mar 31, 2022 | 31.87 Mn |
| Dec 31, 2021 | 28.81 Mn |
| Sep 30, 2021 | 29.38 Mn |
| Jun 30, 2021 | 29.08 Mn |